Heron TherapeuticsHRTX
About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Employees: 122
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
7,109% more call options, than puts
Call options by funds: $4.61M | Put options by funds: $64K
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
4.88% less ownership
Funds ownership: 80.45% [Q3] → 75.58% (-4.88%) [Q4]
6% less funds holding
Funds holding: 172 [Q3] → 161 (-11) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 49
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
28% less capital invested
Capital invested by funds: $243M [Q3] → $176M (-$67M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Needham Serge Belanger 46% 1-year accuracy 55 / 120 met price target | 72%upside $4 | Buy Reiterated | 28 Feb 2025 |
Financial journalist opinion
Based on 4 articles about HRTX published over the past 30 days









